Genetic Signatures is ceasing development of its EasyScreen Essentials Respiratory Detection Kit for the US market. The move follows an internal review of the highly competitive market and evolving dynamics.

The decision results in the discontinuation of US clinical development activities for this product and the withdrawal of plans to file for Food and Drug Administration 510(k) clearance.

The development follows the surge in molecular testing during the COVID-19 pandemic and the subsequent decline in demand over the past 24 to 36 months.

Genetic Signatures will concentrate on launching its EasyScreen Gastrointestinal Parasite Detection Kit in the US.